Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Payables (2016 - 2025)

Historic Payables for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $1.8 million.

  • Dare Bioscience's Payables rose 7592.25% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 7592.25%. This contributed to the annual value of $1.5 million for FY2024, which is 5699.87% down from last year.
  • Per Dare Bioscience's latest filing, its Payables stood at $1.8 million for Q3 2025, which was up 7592.25% from $1.8 million recorded in Q2 2025.
  • Over the past 5 years, Dare Bioscience's Payables peaked at $6.5 million during Q2 2023, and registered a low of $216043.0 during Q2 2021.
  • For the 5-year period, Dare Bioscience's Payables averaged around $2.4 million, with its median value being $1.9 million (2024).
  • Per our database at Business Quant, Dare Bioscience's Payables crashed by 8962.01% in 2021 and then soared by 48705.35% in 2023.
  • Dare Bioscience's Payables (Quarter) stood at $2.1 million in 2021, then decreased by 3.57% to $2.0 million in 2022, then soared by 66.94% to $3.4 million in 2023, then plummeted by 57.0% to $1.5 million in 2024, then increased by 26.72% to $1.8 million in 2025.
  • Its Payables was $1.8 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.